Madrigal Pharmaceuticals (MDGL)
(Delayed Data from NSDQ)
$225.49 USD
+2.98 (1.34%)
Updated May 30, 2024 04:00 PM ET
After-Market: $225.27 -0.22 (-0.10%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Madrigal Pharmaceuticals, Inc. [MDGL]
Reports for Purchase
Showing records 81 - 100 ( 184 total )
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Phase 3 NASH Study of Resmetirom Underway; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare - Part 2: Digging Through ICPT EASL Abstracts
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
NASH Weekly: Should You Go to EASL With Late Breakers Abstracts Revealed?
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Reasons Why You Can''t Miss Our 2nd Battle of NASH Thrones Conference on Mar. 28
Provider: Roth Capital Partners, Inc.
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare - Part 1 - Which NASH Companies to See and Why at Our 31st ROTH Conference?
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
4Q Recap: Phase 3 NASH Trial to Begin This Quarter; Affirm Buy, Reduce PT to $228
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare: Kick off EASL by Joining our Battle of the NASH Thrones Investor Conference
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare - NASH Weekly: Our Christmas Gift to You!
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Takeaways From Recent Investor Dinner With Management; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare -Yas'' Weekly Recap - What the Buy-side Reads
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare - NASH Weekly: Who Should You Listen to - MDGL Bears or Bulls?
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare - Yas'' Weekly Recap - What the Buy Side Reads
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Live From AASLD - We Asked For More, We Got More
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
36-Week Phase 2 Data Presented; Expectations for Tonight''s Analyst Event
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y